Keywords
Errores innatos del Metabolismo
Atención médica,
Telemedicina.
How to Cite
Abstract
The impact of the SARS-CoV-2 pandemic has generated a change in the medical care of several diseases in many health centers. Inborn errors of metabolism (IEM) are genetic diseases that constitute chronic conditions, requiring continuous follow-up and highly complex treatments. In addition, it has been suggested that these pathologies could constitute a risk factor for the development of complications due to COVID-19 infection. In order to identify how the pandemic has affected population with IEM, 17 articles have been analyzed documenting the effects of the SARS-CoV-2 virus on health, treatment, medical care and lifestyle of patients with IEM. Our results provide an insight into the knowledge of the situation of this group of patients, observing that, contrary to expectations, there is a positive outlook in terms of the disease course in the IEM population, although some disadvantages in medical care were documented. These results highlight the importance of analyzing and reporting the available evidence to provide information that contributes to the improvement of patient care and counseling based on specific realities and needs.
Lamas-Barreiro, J.M., et al., Supresión de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica. nefrologia, 2020. 40(3): p. 213.
Abelson, A., Are we sacrificing the future of coral reefs on the altar of the “climate change” narrative? ICES Journal of Marine Science, 2020. 77(1): p. 40-45.
Dong, E., H. Du, and L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. The Lancet infectious diseases, 2020. 20(5): p. 533-534.
Elmonem, M.A., et al., The impact of COVID-19 pandemic on the diagnosis and management of inborn errors of metabolism: A global perspective. Molecular genetics and metabolism, 2020. 131(3): p. 285-288.
Barrera Avellaneda, L.A., et al., Errores innatos del metabolismo: un abordaje integral del diagnóstico al tratamiento. 1 ed. 2014: Editorial Pontificia Universidad Javeriana. 446.
Ferreira, C.R., et al., An international classification of inherited metabolic disorders (ICIMD). J Inherit Metab Dis, 2021. 44(1): p. 164-177.
Sanchéz, M., M.L. Tamara, and J.D. Serra, Errores innatos del metabolismo: aproximación diagnóstica en Atención Primaria. Bol pediatr, 2007. 47(200): p. 111-115.
Mistry, P., et al., Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. Molecular genetics and metabolism, 2020. 130(3): p. 164.
Domingo Lamuño, G., et al. Recomendaciones de las sociedades Aecom y Seeim para la escolarización de niños con Errores Innatos del Metabolismo durante la pandemia Covid-19. 2020 [cited 2021 4 de octubre].
Clayton, P.T., Is susceptibility to severe COVID-19 disease an inborn error of metabolism? Journal of Inherited Metabolic Disease, 2020.
Brunetti-Pierri, N., et al., Ensuring continuity of care for children with inherited metabolic diseases at the time of COVID-19: the experience of a metabolic unit in Italy. Genetics in Medicine, 2020. 22(7): p. 1178-1180.
Colombo, C., et al., Impact of COVID-19 on people with cystic fibrosis. The Lancet Respiratory Medicine, 2020. 8(5): p. e35-e36.
Carter-Timofte, M.E., et al., Deciphering the role of host genetics in susceptibility to severe COVID-19. Frontiers in immunology, 2020. 11: p. 1606.
Peckham, D., et al., COVID-19 meets Cystic Fibrosis: for better or worse? Genes & Immunity, 2020. 21(4): p. 260-262.
Bezzerri, V., et al., Does cystic fibrosis constitute an advantage in COVID-19 infection? Italian Journal of Pediatrics, 2020. 46(1): p. 1-3.
Caciotti, A., et al., SARS-CoV-2 infection in a patient with propionic acidemia. Orphanet Journal of Rare Diseases, 2020. 15(1): p. 1-5.
Enver, E.O., et al., Challenges of following patients with inherited metabolic diseases during the COVID-19 outbreak. A cross-sectional online survey study. Journal of Pediatric Endocrinology and Metabolism, 2021. 34(1): p. 103-107.
Stanescu, S., et al., Successful Remote Monitoring During COVID-19 Pandemic of Patients with Inborn Errors of the Amino acid Metabolism not including PKU from a Single Reference center using Filter Paper Samples. 2020.
Fierro, L., et al., Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York. Molecular Genetics and Metabolism, 2021. 132(1): p. 44-48.
Schwartz, I.V.D., et al. SARS‐CoV‐2 pandemic in the Brazilian community of rare diseases: A patient reported survey. in American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2021. Wiley Online Library.
Meyts, I., et al., Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. Journal of Allergy and Clinical Immunology, 2021. 147(2): p. 520-531.
Vitturi, N., et al., SARS CoV2 infection in a young subject affected by arginosuccinate synthase deficiency: A case report of epilepsy worsening, in Mol Genet Metab Rep. 2021, © 2020 The Authors. Published by Elsevier Inc. p. 100698.
Kahl, G., et al., COVID-19 y mirada desde la fibrosis quística. Rev. am. med. respir, 2020: p. 50-55.
López, S.G., et al., Atención de pacientes con errores innatos del metabolismo durante la pandemia de COVID-19 en México: importancia de la telemedicina. Acta Pediátrica de México, 2021. 42(1): p. 11-20.
Colquicocha-Murillo, M., et al., Guía para diagnóstico y tratamiento de la Enfermedad de Gaucher. Revista Medica Herediana, 2015. 26(2): p. 103-121.
Andrade-Campos, M., et al., Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies? Blood Cells Mol Dis, 2020. 85: p. 102478.
Flume, P.A., Pulmonary complications of cystic fibrosis. Respiratory care, 2009. 54(5): p. 618-627.
Irago, J.A.D.S., España hace historia aprobando Kaftrio, el tratamiento que cambiará las vidas de muchas personas con Fibrosis Quística. 2021, Sociedad española de Fibrosis Quística.
Mijović, B.P., COVID-19–lessons learned. Scripta Medica, 2020. 51(1): p. 1-5.
Penna, C., et al., Sex‐related differences in COVID‐19 lethality. British journal of pharmacology, 2020. 177(19): p. 4375-4385.
Vitturi, N., et al., SARS CoV2 infection in a young subject affected by arginosuccinate synthase deficiency: A case report of epilepsy worsening. Molecular Genetics and Metabolism Reports, 2021. 26: p. 100698.
Tummolo, A., et al., COVID-19 and Inherited Metabolic Disorders: One-Year Experience of a Referral Center. Children, 2021. 8(9): p. 781.
Chung, C.C.Y., et al., A thematic study: impact of COVID-19 pandemic on rare disease organisations and patients across ten jurisdictions in the Asia Pacific region. Orphanet Journal of Rare Diseases, 2021. 16(1): p. 1-12.
Tobór-Świętek, E., et al., COVID-19 Pandemic and Patients with Rare Inherited Metabolic Disorders and Rare Autoinflammatory Diseases—Organizational Challenges from the Point of View of Healthcare Providers. Journal of clinical medicine, 2021. 10(21): p. 4862.
Lampe, C., et al., The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys. Orphanet journal of rare diseases, 2020. 15(1): p. 1-14.
Hulley, S., et al., The Impact of SARs-CoV2 infection on paediatric patients with Inherited Metabolic Diseases in the UK: The first 14 months., in XIV International Congress of Inborn Errors of Metabolism. 2021: Sydney, Australia.
Lampe, C., et al., The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys. Orphanet journal of rare diseases, 2020. 15(1): p. 1-14.
Perú, M.d.s.d., Protocolo para la vacunación contra la covid-19 para personas mayores de 12 aros, que padecen enfermedades raras y huérfanas. 2021: Perú.
Vaccinations against COVID-19 and PKU. 2021 [cited 2021; Available from: https://www.espku.org/2021/01/16/vaccinations-against-covid-19-and-pku/.
Kumar, N., et al., Is glucose-6-phosphatase dehydrogenase deficiency associated with severe outcomes in hospitalized COVID-19 patients? 2021.
Oymak, Y., T.H. Karapinar, and I. Devrim, Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine? Journal of Pediatric Hematology/Oncology, 2021. 43(1): p. 35-36.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Daniel F. Cancino Ricketts, Juliana Ríos Mora, Laura Camila Sáenz Díaz, Olga Yaneth Echeverri Peña, Johana Guevara Morales